Phuturdex › Diseases › Immunologic Deficiency Syndromes
Drugs in development · updated 30 October 2026
Immunologic Deficiency Syndromes: drugs in development
As of 30 October 2026 there are 13 active clinical trials (recruiting or ongoing, phases I–III) on 17 drugs for immunologic Deficiency Syndromes. 6 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BriquilimabJSP191 | II | 1 | NCT05907746 |
| MTP 101-LF | I–II | 1 | NCT05333471 |
| TabelecleucelEbvallo® | II | 1 | NCT04554914 |
| BG505 | I | 1 | NCT05217641 |
| SB-728mR-HSPC | I | 1 | NCT02500849 |
| CD19 | Early I | 1 | NCT02356653 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BusulfanBusulphan, Busulfex® | I–II | 4 | NCT07775313 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 4 | NCT01176006 |
| FludarabineFludara, FLUDARABIN | II | 4 | NCT01176006 |
| Mycophenolate MofetilMycophenolate, Cellcept | II | 3 | NCT01861106 |
| TacrolimusEnvarsus XR, Prograf® | II | 3 | NCT01861106 |
| Paxlovid | II | 2 | NCT05587894 |
| FilgrastimRecombinant Human Granulocyte Colony-Stimulating Factor, Neupogen | I–II | 1 | NCT07775313 |
| PaliferminKepivance® | I–II | 1 | NCT07775313 |
| PlerixaforMozobil, Plerixafor Accord® | I–II | 1 | NCT07775313 |
| RemdesivirVeklury | II | 1 | NCT05587894 |
| UpadacitinibRinvoq Lq®, Rinvoq® | I–II | 1 | NCT07670156 |
Sorted by most advanced phase and number of active trials.
All 17 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- HIV infection 84 drugs
- Acquired Immunodeficiency Syndrome 61 drugs
- Hereditary angioedema 8 drugs
- Chronic granulomatous disease 21 drugs
- Primary immunodeficiency disease 13 drugs
- Common variable immunodeficiency 14 drugs
- Kaposi's sarcoma 15 drugs
- Hematologic neoplasm 216 drugs
- Agammaglobulinemia 11 drugs
- Infection 71 drugs
- Non-Hodgkin lymphoma 269 drugs
- Severe combined immunodeficiency 8 drugs
Broader categories
- Immune System Diseases 54 drugs
- Infection 71 drugs
- Hematologic Diseases 57 drugs
- Virus Diseases 26 drugs
- Urogenital Diseases 16 drugs
- Lung disease 104 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D007153 “Immunologic Deficiency Syndromes”.